ProxsysRx’s process for recovering lost 340B savings and revenue As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are … Read More
Opening an onsite specialty pharmacy is extremely challenging — particularly given the effort required just to get access to purchase specialty meds, and then to get “In Network” with PBMs. That said, ProxsysRx has developed a proven process for meeting those challenges. Owning a successful specialty pharmacy starts with optimizing your 340B program (For an … Read More
Since 2019, ProxsysRx has generated more than $500 million in 340B savings and revenue for the health systems we serve — and yes, we’ve learned to overcome many of even the toughest manufacturers restrictions. We work with hospitals to unlock pharmacy’s potential throughout the continuum of care. We optimize revenues from their 340B programs and … Read More
Below are highlights of an in-depth roundtable discussion outlining how eligible health systems can ensure the success of their onsite specialty pharmacies. To watch videos of that discussion, organized by topic, Click Here. You can also find a curated transcript of the entire discussion here. Nurture strong pharmacist / provider relationships It’s critical that you … Read More
What we’ve learned. What it means for your 340B program. Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. In spite of drug manufacturer restrictions, every one of the 13 health systems we … Read More
